Optimi Health Corp. announced it has entered an international MDMA supply agreement with The Institute for Psychedelic Research at Tel Aviv University (IPR-TLV), marking the company's maiden venture into the Israeli market. In this collaboration, Optimi will supply IPR-TLV with MDMA, which was made from in-house produced active pharmaceutical ingredient (API), to support the institute's research investigating the effects of MDMA on animal models of alcohol addiction.

Optimi has received the import permit from IPR-TLV and is in the process of obtaining its export permit from Health Canada. Expected to commence in the summer of 2024 and conclude in late 2025, this study aligns with Optimi's commitment to supplying MDMA to international researchers advancing mental health and addictions research. The outcomes of the study, including abstracts at scientific gatherings, preprints, and peer-reviewed articles, will contribute to the academic discourse surrounding the therapeutic potential of MDMA.